EQL Pharma AB (EQL) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for EQL Pharma AB (STO:EQL), currently being evaluated. In 2026, EQL Pharma AB generated $432.66 Million in revenue and -$38.88 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for EQL Pharma AB is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2026): $432.66 Million
- Free Cash Flow (2026): -$38.88 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.